Pfizer Invests $6.7 Billion in Medical Cannabis

The American laboratory Pfizer joined Jazz Pharma and the laboratory Johnson & Johnson in the race to conquer the medical cannabis market. Indeed, Pfizer has just acquired another laboratory specializing in the production of medicines based on cannabis in the United States.

Read more about Pfizer and find other important cannabis news with the Hemp.im mobile app. The app makes it easy for you to keep informed, to intuitively move from story to story, and from section to section. Its clean design lets you read articles without clutter, and use the app with no limits on how many articles you can view.

The new acquisition of the pharmaceutical giant Pfizer is called Arena Pharmaceuticals

According to Forbes: “Under the agreement terms, Pfizer acquires all shares for $100 per share in an all-cash transaction. Moreover, the press release reads that the proposed transaction will be subject to customary closing conditions, including receipt of regulatory approvals and approval by Arena’s stockholders.”

Arena Pharmaceuticals is an American company that produces drugs from its headquarters in San Diego, California, since 2012. One of the treatments for irritable bowel syndrome, called Olorionab, is based on cannabis and is in Arena Pharmaceuticals’s development pipeline.

Specializing in experimental treatments for Crohn’s disease, Arena Pharmaceutical has only one marketing authorization in the USA. Since 2012 it has been marketing the molecule it patented: Lorcaserin. It is in fact a treatment to fight against obesity. The name of this drug is ‘Belviq’.

Pfizer doesn’t need any introduction. The multinational company’s profits are expected to be stratospheric this year, thanks to its global vaccine trial on COVID that ends in 2023. On the acquisition side, the patent that Pfizer is interested in is the treatment called Olorinab. This involves using cannabinoids via human CB2 receptors against pain and symptoms of inflammation in the abdominal area.

The biotechnology company managed to raise $6.7 billion to carry out research on drugs based on cannabinoids and becomes in some way the specialized unit of Pfizer in the field of drugs based on cannabis.

7 billions, to give you an idea, it is the equivalent of the French trade deficit for one year. While the multinationals are investing, France is cutting itself off from any hope of research or development in this sector by starting to ban hemp flowers, for example. The startup nation will therefore suffer the will of the multinationals for its medical cannabis-based treatments for lack of development and funded initiative in this direction.

__

(Featured image by Marco Verch Professional Photographer CC BY 2.0 via Flickr)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Le Cannabiste, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.